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Tumor microenvironment conditions alter
Akt and Na+/H+ exchanger NHE1
expression in endothelial cells more than
hypoxia alone: implications for endothelial
cell function in cancer
A. K. Pedersen1, J. Mendes Lopes de Melo1, N. Mørup1, K. Tritsaris1*† and S. F. Pedersen2*†
Abstract
Background: Chronic angiogenesis is a hallmark of most tumors and takes place in a hostile tumor microenvironment
(TME) characterized by hypoxia, low nutrient and glucose levels, elevated lactate and low pH. Despite this, most studies
addressing angiogenic signaling use hypoxia as a proxy for tumor conditions. Here, we compared the effects of
hypoxia and TME conditions on regulation of the Na+/H+ exchanger NHE1, Ser/Thr kinases Akt1–3, and downstream
effectors in endothelial cells.
Methods: Human umbilical vein endothelial cells (HUVEC) and Ea.hy926 endothelial cells were exposed to simulated
TME (1% hypoxia, low serum, glucose, pH, high lactate) or 1% hypoxia for 24 or 48 h, with or without NHE1 inhibition
or siRNA-mediated knockdown. mRNA and protein levels of NHE1, Akt1–3, and downstream effectors were assessed by
qPCR and Western blotting, vascular endothelial growth factor (VEGF) release by ELISA, and motility by scratch assay.
Results: Within 24 h, HIF-1α level and VEGF mRNA level were increased robustly by TME and modestly by hypoxia
alone. The NHE1 mRNA level was decreased by both hypoxia and TME, and NHE1 protein was reduced by TME in Ea.
hy926 cells. Akt1–3 mRNA was detected in HUVEC and Ea.hy926 cells, Akt1 most abundantly. Akt1 protein expression
was reduced by TME yet unaffected by hypoxia, while Akt phosphorylation was increased by TME. The Akt loss was
partly reversed by MCF-7 human breast cancer cell conditioned medium, suggesting that in vivo, the cancer cell
secretome may compensate for adverse effects of TME on endothelial cells. TME, yet not hypoxia, reduced p70S6 kinase
activity and ribosomal protein S6 phosphorylation and increased eIF2α phosphorylation, consistent with inhibition of
protein translation. Finally, TME reduced Retinoblastoma protein phosphorylation and induced poly-ADP-ribose
polymerase (PARP) cleavage consistent with inhibition of proliferation and induction of apoptosis. NHE1 knockdown,
mimicking the effect of TME on NHE1 expression, reduced Ea.hy926 migration. TME effects on HIF-1α, VEGF, Akt,
translation, proliferation or apoptosis markers were unaffected by NHE1 knockdown/inhibition.
Conclusions: NHE1 and Akt are downregulated by TME conditions, more potently than by hypoxia alone. This inhibits
endothelial cell migration and growth in a manner likely modulated by the cancer cell secretome.
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Background
Chronic angiogenesis is a hallmark of most cancers. With
the possible exception of a few “hypovascular” cancers
such as pancreatic adenocarcinomas, the “angiogenic
switch” – the onset of tumor angiogenesis – is essential
for continued tumor growth [1–3]. Accordingly, angiogen-
esis inhibitors have shown efficacy in restricting both pri-
mary tumor growth and metastasis in many types of
cancers in preclinical models. Several anti-angiogenic
compounds are in clinical use and are initially effective,
yet generally fail to produce a lasting response [1–4].
Hypoxic conditions arise as soon as the tumor grows
beyond a few hundred μm in diameter. Hypoxia in-
creases the protein level and activity of the transcription
factor Hypoxia-Inducible Factor 1α (HIF-1α), in turn in-
ducing the upregulation of Vascular Endothelial Growth
Factor (VEGF) A and VEGF receptor 2 (VEGFR2) in the
endothelial cells, resulting in endothelial cell prolifera-
tion and angiogenesis [5, 6]. In tumors, the cancer cells
are a major source of secreted VEGF, further stimulating
angiogenesis [2]. In congruence with the central role of
VEGF, the humanized, VEGF-neutralizing monoclonal
antibody bevacizumab is approved for treatment of sev-
eral cancers, including late-stage colon cancer and breast
cancer, in conjunction with chemotherapy [1, 7].
In addition to being hypoxic, the tumor microenviron-
ment (TME) is characterized by acidic extracellular pH
(pHe), low glucose and nutrient levels, elevated lactate
levels, and the presence of multiple cytokines and
growth factors, including VEGF, secreted by the various
cell types present in the tumor [8]. Notably, while hyp-
oxia in isolation is often taken as relevant to cancer biol-
ogy, other chemico-physical conditions of the TME
(hypoxia, acidic pH, low glucose, high lactate) can exert
profoundly different gene-regulatory effects than hypoxia
alone [9–12], yet have been much less studied. The dys-
regulation of pHe results from increased metabolic acid
production in, and net acid extrusion from, the cancer
cells, in conjunction with poor diffusion in the TME.
This results in pHe as low as 6.2–6.5 [13, 14]. The in-
creased acid extrusion from the cancer cells reflects the
upregulation and increased activity of several acid–base
transport proteins, including the Na+/H+ exchanger
NHE1 [13–15]. NHE1 has been shown to contribute to
increased motility, invasiveness, proliferation and sur-
vival in a wide range of cancer cell types [13–18]. Fur-
thermore, NHE1 was recently assigned a role in VEGF
secretion from KN562 leukemia cells [19, 20]. In con-
trast, the role of NHE1 in tumor endothelial cells is es-
sentially unknown. NHE1 is expressed in various types
of endothelial cells and contributes to their intracellular
pH (pHi) regulation and consequently to endothelial
function [21–24]. NHE1 was reported to be upregulated
by exogenous expression of HIF-1α in Human Umbilical
Vein Endothelial Cells (HUVEC) [25], and its pharmaco-
logical inhibition or knockdown was found to attenuate
HIF-1α-induced HUVEC proliferation, migration and tube
formation [25]. Furthermore, NHE1 expression and activ-
ity were upregulated by hypoxia, aglycemia, or vasopressin
in blood–brain barrier endothelial cells [24]. In non-
endothelial cells, the impact of hypoxia on NHE1 is con-
troversial. Initial reports found NHE1 expression to be in-
creased in a HIF-1α-dependent manner in pulmonary
arterial myocytes [26], whereas a later report in a wide
array of cancer cell lines found NHE1 expression to be ei-
ther downregulated or unaffected by hypoxia [27].
The Ser/Thr kinase Akt, acting downstream from acti-
vation of VEGFR2, plays central roles in regulation of
endothelial cell function, including the control of vessel
growth and homeostasis [5, 28, 29]. Three closely related
Akt isoforms, Akt1–3, are expressed in mammalian cells,
Akt1 being the most abundant and widely expressed.
The three isoforms are structurally similar, yet exhibit
functional differences in several cell types including
endothelial cells [30–32]. Akt is an important regulator
of cell growth, in part via its ability to stimulate the
phosphorylation of the p70S6 kinase (p70S6K), leading
to ribosomal protein S6 (rpS6) phosphorylation [33].
Notably, in non-endothelial cells, NHE1 has been shown
to recruit and activate Akt [34] and, conversely, to
be phosphorylated by Akt suggesting that these two
important regulators of endothelial function might be
functionally linked.
Thus, NHE1 and Akt are important for endothelial cell
function, and are regulated, directly or indirectly, by
hypoxia. However, the impact of hypoxia on NHE1 is con-
troversial, and the impact of the more complex physi-
cochemical TME on NHE1 and Akt in endothelial cells
has, to our knowledge, never been studied. Here, we com-
pared the effect of hypoxia alone to that of TME on
NHE1 and Akt1–3 in primary endothelial cells and an
endothelial cell line, and assessed the effect of pharmaco-
logical and siRNA-mediated NHE1 inhibition on Akt ex-
pression, activity, and endothelial cell function. We report
that NHE1, Akt, and protein translation signaling are
downregulated much more potently by TME conditions
than by hypoxia alone, and that this inhibits endothelial
cell migration, proliferation and survival, in a manner
likely to be modulated by the cancer cell secretome.
Methods
Cell lines and culture conditions
Primary human umbilical vein endothelial cells
(HUVEC, [35]) from pooled donors (Lonza, CC-2519)
were cultured in gelatine-coated cell culture flasks in
EBM basal medium (Lonza) supplemented with EGM
singleQuot supplement and growth factors (Lonza).
Cells were maintained at 37 °C under 5% CO2 and 95%
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humidity and experiments were performed with cells in
passage 4–9. The hybrid EA.hy926 cell line, generated
by fusion of HUVEC with cells of the lung carcinoma
cell line A549 [36], was cultured in 1% gelatine-coated
cell culture flasks in DMEM 1965 medium supple-
mented with 10% fetal bovine serum (FBS) and 1% peni-
cillin/streptomycin. Cells were maintained like HUVEC
and not used above passage 20.
Cell culture and model system
Under experimental conditions, cells were grown in
RPMI-1640 (Sigma-Aldrich). For control conditions
RPMI-1640 was supplemented with 5% FBS, 10 mM glu-
cose, 5 mM NaCl, 1% penicillin/streptomycin and
24 mM HCO3
− to reach a pH of 7.4 when equilibrating
with 5% CO2 (control (ctrl) medium). To mimic tumor
microenvironment (TME) conditions RPMI-1640 was
supplemented with 1% FBS, 2.5 mM glucose, 10 mM
NaCl, 7.5 mM Sodium Lactate (NaL), 1% penicillin/
streptomycin and 3 mM HCO3
− to equilibrate to a pH of
6.5 when incubated with 5% CO2 (TME medium). For
experiments, cells were grown in 1% gelatine-coated
dishes in regular growth medium, washed with PBS and
incubated with either control or TME medium for 24 or
48 h. Control cells were kept at 37 °C with 5% CO2 and
95% humidity. Cells in TME medium were incubated in
a computer-controlled workspace/incubator system
(Xvivo G300C, Biospherix) at 37 °C with 5% CO2 and
94% humidified Nitrogen (N2) and 1% O2, essentially as
previously described [37]. For hypoxia alone, cells in
control medium were exposed to 5% CO2 and 94% N2
and 1% O2 as described for the TME cells. For functional
inhibition of NHE1, cells were treated with 10 μM car-
iporide (a kind gift from Sanofi Aventis). Cariporide was
dissolved at 10 mM in ddH2O. MCF-7 human breast can-
cer cells (a kind gift from Dr. Lone Ronnov-Jessen, Uni-
versity of Copenhagen) were grown in standard low
glucose (5.5 mM) DMEM 1885 (SSC, University of
Copenhagen, Cat. 22–2-24, #015) supplemented with 6%
FBS (Gibco), 1% Pen/Strep (Invitrogen), and 1% MEM
Non-Essential Amino Acids 100X (Gibco/Invitrogen), at
37 °C, 95% humidity, 5% CO2. For TME experiments, cells
were seeded in culture dishes and exposed to TME
medium as above for 24 or 48 h.
SDS-PAGE and western blotting
For western blotting, cells were washed in ice-cold PBS
and lysed with SDS lysis buffer (1% SDS, 10 mM Tris–
HCl, 1 mM Na3VO4, pH 7.5). The cell lysate was ho-
mogenized by sonication and centrifuged for 10 min at
13,000 g. Protein contents were quantified using the
Bio-Rad DC protein assay kit (Bio-Rad) and samples
were diluted to equal protein concentrations, with water
and 1X loading buffer (Invitrogen), containing
dithiothretiol (DTT) (Sigma-Aldrich). Proteins were sep-
arated by SDS-PAGE gel electrophoresis (NuPAGE 4–
12% Bis-Tris gels) under denaturing and reducing condi-
tions (NuPAGE MES SDS running buffer) (Invitrogen).
Proteins were transferred onto nitrocellulose membranes
with transfer buffer containing 20% methanol. Mem-
branes were blocked in 5% milk protein in PBS-Tween
(1xPBS with 0.1% Tween-20) for 2 h at room temperature
and incubated with primary antibody diluted in PBS-
Tween with 5% BSA and 0,1% NaN3 overnight at 4 °C.
Primary antibodies used were rabbit anti-phospho(p)-
Ser473Akt (#9271), rabbit anti-Akt1 (#2962), rabbit anti-
p-Ser51 eIF2α (#9721), rabbit anti-GAPDH (#2118),
mouse anti-pThr389-p70S6K (#9206), rabbit anti-p70S6K
(#2708), rabbit anti-poly-ADP-ribose polymerase (PARP)
(#9542), rabbit anti-p-Ser807/811-pRb (#9308), and rabbit
anti-p-Ser235/236-rpS6 (#4856) purchased from Cell Sig-
naling Technology; mouse anti-p-Thr202/Tyr204-ERK1/2
(#7383) and mouse anti-NHE1 (clone 54) purchased from
Santa Cruz Biotechnology; mouse anti-GAPDH (CB1001)
purchased from Millipore; mouse anti-HIF-1α (#610958)
and mouse anti-p150 (#610473) purchased from BD
Transduction Laboratories. Membranes were incubated
with horseradish peroxidase-conjugated secondary anti-
body (Dako; goat-anti-mouse IgG, #P0447, goat-anti-
rabbit IgG, #P 0448) diluted in 1% milk protein in
PBS-Tween for 1 h at room temperature and developed
with Supersignal West Pico chemiluminescent sub-
strate or Supersignal West Femto maximum sensitivity
substrate (Thermo Fisher Scientific) using the UVP
Biospectrum chemiluminescence Imaging system. Im-
ages were obtained using the VisionWorksLS software
and UN-SCAN-IT 6.1 (Silk Scientific) was utilized to
quantify the intensity of the protein bands.
qPCR analysis
Total RNA was purified using the RNeasy mini kit (Qia-
gen) and the RNase free DNase set (Qiagen), and reverse
transcription was performed using the Omniscript RT
mini kit (Qiagen), all according to the instructions of the
manufacturer. cDNA was amplified by quantitative PCR
using LightCycler 480 SYBR Green I Master Mix (Roche
Applied Sciences), according to the instructions of the
manufacturer. Reactions were carried out in triplicates
on a Stratagene Mx3005P QPCR system from Agilent
Technologies (95 °C 10 min, 40 cycles of 95 °C 20 s, an-
nealing temperature 58–64 °C depending on primers
22 s and 72 °C 20 s). The following primer pairs were
used: 5′-CTTTGCCGGTATCGTGTGGC-3′ (forward)
and 5′-CTCGCTGTCCACACACTCCA-3′(reverse) to
generate an Akt1 fragment of 172 bp; 5′-TCAAAG
AAGGCTGGCTCCAC-3 (forward) and 5′-GGCCTC
TCGGTCTTCATCAG-3 (reverse) to generate an Akt2
fragment of 184 bp; 5′-CACCACCTGAAAAATATGAT
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GAGGA-3 (forward) and 5′-GGTGCCCCTGCTATGT
GTAA-3 (reverse) to generate an Akt3 fragment of
200 bp; 5′-GGAAGGTGAAGGTCGGAGTCAA-3′(for-
ward) and 5′-GATCTCGCTCCTGGAAGATGCAT-
3′(reverse) to generate a GAPDH fragment of 240 bp;
5′-CACACCACCATCAAATACTTCC-3′(forward) and
5′-GAACTTGTTGATGAACCAGGTC-3′ to generate
an NHE1 fragment of 192 bp; and 5′-GCGTTGC
AAGGCGAGGCAGC-3′(forward) and 5′-TGGTGGC
GGCAGCGTGGTTT-3′(reverse) to generate a VEGF
fragment of 172 bp. Amplification of specific targets
were verified by agarose-gel electrophoresis. A standard
curve of 4× serial dilutions of cDNA was made for each
of the utilized primer-sets and the Pfaffl method was
applied for relative quantification of the qPCR results,
using GAPDH as the reference gene.
siRNA-mediated knockdown of NHE1
NHE1 siRNA (NM_003047; SASI_Hs01_00025997) and
universal negative control siRNA (SIC001) were ob-
tained from Sigma-Aldrich. For siRNA transfection,
EA.hy926 cells were grown to 50–60% confluency in
gelatine-coated culture dishes and transfected with
NHE1 siRNA (50 nM) or scrambled siRNA (50 nM),
using the N-TER nanoparticle siRNA transfection sys-
tem (Sigma-Aldrich), according to the instructions of
the manufacturer. For western blotting and qPCR cells
were lysed 48 h post transfection.
ELISA assay for VEGF release
VEGF concentration in conditioned medium was deter-
mined using the human VEGF DuoSet ELISA Develop-
ment kit (R&D Systems), according to the instructions
of the manufacturer. In short, the plate was coated with
a capture antibody against VEGF followed by blocking of
the wells with reagent diluent (PBS with 1% BSA). Next,
samples were added to the plate and bound VEGF was
detected with biotinylated detection antibody, followed
by addition of streptavidin conjugated to HRP. In be-
tween each step the plate was washed 3 times with wash
buffer (PBS with 0.05% Tween-20). Substrate solution
(R&D Systems) was added to the plate, reaction was
stopped with 2 N sulfuric acid (H2SO4) and the optical
densities of the wells were determined at 450 nm on a
Synergy HT microplate reader from BioTek, with wave-
length correction set to 540 nm. The amount of VEGF
in the samples was quantitatively determined according
to a 7-point standard curve of 2× serial dilutions of
known concentrations. Both standards and samples were
measured in triplicates.
Scratch assay
An in vitro scratch assay was performed with siNHE1-
transfected EA.hy926 cells, essentially as described in
[38]. In short, cells were grown to 50–60% confluency
before transfection with NHE1 siRNA. Cells were then
incubated for 48 h, where after a scratch was made in
the cell monolayer and cell movement and wound clos-
ure were monitored at different time intervals. After
scratch induction cells were washed with PBS, changed
to fresh complete medium and left to adapt for approxi-
mately 6 h (during which no change was observed). Im-
ages of wound area used for quantification were
acquired after adaptation (considered t = 0) and at
t = 18 h. Visualization and image acquisition were per-
formed using a Leitz Labovert phase-contrast micro-
scope (Leica Microsystems) and a digital camera
(CoolPix 990, Nikon).
Statistical analysis
Results are presented as representative individual ex-
periments or as mean values with error bars showing
standard error of means (SEM). Statistical analysis was
done with GraphPad Prism using either two-way or
one-way analysis of variance (ANOVA) with Tukey’s or
Bonferroni’s multiple comparison post-test, a one-sample
t-test (Fig. 4a) or a two-tailed paired Students t-test, as in-
dicated in the figure legends. Statistically significant results
are marked with *, **, *** or **** denoting p < 0.05,
p < 0.01, p < 0.001 or p < 0.0001, respectively.
Results
TME conditions upregulate HIF-1α more than hypoxia
alone and independent of NHE1
We first determined the effect of hypoxia and TME con-
ditions on HIF-1α and VEGF levels. HUVEC, primary
human endothelial cells, were exposed to either hypoxia
alone (Hyp, 1% O2) or TME conditions (1% O2, 1% FBS,
2.5 mM glucose, 7.5 mM lactate, pHe 6.5) for 24 h. Be-
cause of the proposed role of NHE1 in HIF-1α signaling
in endothelial cells [25], we assessed the effect of these
treatments in the absence and presence of NHE1 inhib-
ition/knockdown. After exposure to hypoxia or TME for
24 h, HUVEC cells were lysed, followed by western blot-
ting for HIF-1α (Fig. 1a). Notably, whereas hypoxia alone
increased the HIF-1α protein level 7–8 fold compared to
control conditions, TME exposure increased the HIF-1α
level more than 12-fold. Inhibition of NHE1 by caripor-
ide had no effect on the induction of HIF-1α expression
in either condition (Fig. 1a). To determine whether the
greater increase in HIF-1α level during TME compared
to hypoxia was of functional significance, we assessed
the mRNA level of VEGF in HUVEC after both condi-
tions (Fig. 1b). Importantly, similar to the HIF-1α pro-
tein level, the VEGF mRNA level was increased much
more by TME than by hypoxia alone. Consistent with
this, the VEGF mRNA level in Ea.hy926 cells also tended
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to be increased after TME exposure, and this was un-
affected by NHE1 knockdown under both control and
TME conditions (Fig. 1c).
NHE1 knockdown reduces endothelial cell migration
Given the central importance of NHE1 activity for mi-
gration in many cell types [39], we next asked whether
knockdown of NHE1, rather than directly impacting
HIF-1α signaling, affected endothelial cell migration.
Confirming this hypothesis, NHE1 knockdown reduced
wound closure of the Ea.hy926 cells at time 18 h after
introduction of the wound, by about 40% (Fig. 1d).
Collectively, these results show that compared to hyp-
oxia alone, TME conditions strongly potentiate HIF-1α
accumulation, leading to an increased VEGF response.
NHE1 inhibition or knockdown does not affect HIF-1α
accumulation or VEGF production, but reduces endo-
thelial cell migration, suggesting that reduced NHE1
Fig. 1 TME conditions upregulate HIF-1α and VEGF – this is NHE1-independent whereas endothelial cell migration is dependent on NHE1. HUVECs or
Ea.hy926 were grown under normoxic control (Ctrl), simulated tumor microenvironment (TME; 1% O2, 1% FBS, 2.5 mM glucose, 7.5 mM lactate
and pH 6.5) or hypoxic (Hyp; 1% O2) conditions for 24 h, prior to cell lysis and western blotting with primary antibodies against HIF-1α, or RNA
purification, reverse transcription and qPCR with primers against VEGFA165. NHE1 was inhibited by cariporide (10 μM) or knocked down by
siRNA treatment as indicated. a Representative western blot and quantification of HIF-1α protein levels after 24 h relative to the untreated
control. GAPDH is shown as loading control. Quantified data are presented as means with SEM error bars of n = 3–5. ** indicate p < 0.01 compared
to control cells, two-way ANOVA with Bonferroni’s multiple comparison post-test. The two-way ANOVA test also revealed a significant difference
between conditions (Ctrl, TME, Hyp) with p < 0.0001. b, c Quantification of VEGF mRNA levels relative to the untreated control for HUVEC (B)
and Ea.hy926 (C) cells. qPCR analysis was carried out as described in Methods, using GAPDH as housekeeping gene, and analysis was performed
using the Pfaffl method. Data are shown as means with SEM error bars of n = 5. * denotes p < 0.05, one-way ANOVA with Tukey’s multiple comparison
post-test. d Ea.hy926 cells were treated with NHE1 siRNA or scrambled control siRNA for 48 h (for knockdown efficacy, see Fig. 2d), whereafter a scratch
in the culture was made with a sterile pipette tip and cell migration into the wound area monitored. Data are presented as means with SEM error bars
of n = 3. The figure shows representative images and quantification of the wound area 18 h after scratch induction, relative to that of scrambled
control siRNA
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levels in endothelial cells negatively impacts endothelial
cell migration and hence angiogenesis in the TME.
NHE1 is downregulated by hypoxia and TME conditions
Having demonstrated an important role for NHE1 in
endothelial cell migration, we next asked whether hyp-
oxia and TME conditions altered NHE1 expression in
endothelial cells. Notably, the mRNA level of NHE1
was significantly decreased by both TME conditions
and by hypoxia alone (Fig. 2a), whereas these changes
were not reflected at the NHE1 protein level in
HUVEC, neither after 24 h (Fig. 2b) nor after 48 h (Fig.
2c). The specific NHE1 inhibitor cariporide (10 μM)
had no effect on the NHE1 protein level in HUVEC
under any of the conditions tested (Fig. 2b-c). To fur-
ther pursue the effect of TME conditions on NHE1
expression in endothelial cells, we repeated these exper-
iments in the endothelial hybrid cell line Ea.hy926.
Similar to the finding in HUVEC, the NHE1 mRNA
level was decreased by about 50% in Ea.hy926 cells after
TME exposure (Fig. 2d), and in these cells, western
blotting revealed a corresponding reduction in the NHE1
protein level after TME exposure (Fig. 2e). Transfection of
Ea.hy926 cells with NHE1 siRNA strongly reduced both
the mRNA (Fig. 2d) and protein (Fig. 2e) level of NHE1
under both control and TME conditions, compared to
that in mock-transfected controls.
These results show that NHE1 mRNA expression was
reduced by TME exposure in both endothelial cell types,
whereas within the time course of this experiment, the
NHE1 protein level was reduced in Ea.hy926 cells only.
TME conditions strongly downregulate Akt in endothelial
cells
Given the central role of Akt in regulating endothelial
cell function and the proposed role of NHE1 in regula-
tion of Akt, we next asked how hypoxia, TME, and
NHE1 inhibition/knockdown affected Akt expression
and activity. Akt1 was the predominant Akt isoform in
both HUVEC (Fig. 3a, left panel) and Ea.hy926 cells
(Fig. 3a, right panel). Exposure to hypoxia or TME con-
ditions decreased the mRNA level of Akt1 in HUVEC,
by about 35% (hypoxia) and more than 50% (TME), re-
spectively (Fig. 3b). Akt2 and −3 levels showed a similar
pattern. In Ea.hy926 cells, TME downregulated Akt1
and −2 mRNA, but had no apparent effect on Akt3
(Additional file 1: Figure S1).
Also the protein level of Akt1 in HUVEC was potently
decreased by TME exposure, whereas it was apparently
unaffected by hypoxia alone (Fig. 3c). Akt activity was
assessed by western blotting against Akt phosphorylated
on Ser473 (p-Ser473Akt). Notably, it is evident from the
representative blot in Fig. 3c that the p-Ser473Akt level
increases, whereas total Akt1 decreases, in TME condi-
tions, and that hypoxia alone has little effect. Data were
quantified as total cellular Akt1 (middle) and p-Ser473Akt
relative to total Akt1 (bottom). Inhibition of NHE1 by
cariporide had no detectable effect on either Akt1 expres-
sion or Akt phosphorylation. Similarly, in Ea.hy926 cells
(Fig. 3d), the total Akt1 level was decreased by about 50%
after TME conditions, and the p-Ser473Akt/Akt1 ratio
was increased by TME. Knockdown of NHE1 had no sig-
nificant effect on the p-Ser473Akt/Akt1 ratio, consistent
with the pharmacological data.
Taken together, these results show that the physico-
chemical TME exerts profound effects on Akt expres-
sion and activation not seen under hypoxia alone.
Tumor cell conditioned medium exposure increases
protein expression of Akt1 in HUVEC
In the in vivo tumor microenvironment, cancer cells and
stromal cells secrete VEGF and other cytokines and
growth factors that impact endothelial cell function [8].
Consistent with this notion, MCF-7 human breast can-
cer cells grown under TME conditions secreted large
amounts of VEGF, which was detectable in the medium
by ELISA (Fig. 4a). In contrast, VEGF protein was not
detectable in HUVEC medium under these conditions
(not shown), although VEGF mRNA was readily de-
tected in HUVEC lysates (Fig. 1b). We therefore specu-
lated that the secretome from the cancer cells might
counteract the repression of endothelial Akt induced by
the physicochemical TME conditions. To address this,
we exposed HUVEC to conditioned medium from MCF-
7 cells, generated under TME conditions identical to
those used for the endothelial cells. Notably, exposure to
this MCF-7 tumor conditioned medium (MCF-7 CM)
resulted in a nearly 2-fold increase in Akt1 protein in
HUVEC relative to regular TME conditions (Fig. 4b),
whereas it had no effect on NHE1 expression (Fig. 4c).
In conjunction with the TME-induced VEGF mRNA
increase in the endothelial cells shown in Fig. 1 and the
reduction in Akt levels by TME shown in Fig. 3, this re-
sult suggests that although endothelial cells do increase
VEGF production under TME conditions, additional
paracrine stimulation from the cancer cells is important
for endothelial cells to maintain Akt expression under
these conditions.
TME conditions, but not hypoxia, decrease signaling
related to protein synthesis
An important downstream effect of Akt signaling is
endothelial cell growth, a process mediated in large part
through increased translation via phosphorylation and
activation of p70S6K and its substrate the ribosomal
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Fig. 2 NHE1 is downregulated by hypoxia and TME. HUVECs or Ea.hy926 were grown under normoxic control (Ctrl), TME (1% O2, 1% FBS, 2.5 mM
glucose, 7.5 mM lactate and pH 6.5) or hypoxic (Hyp; 1% O2) conditions for 24 h (or 48 h as indicated in panel C). Subsequently, cells were lysed
and subjected to SDS-PAGE and western blotting with primary antibodies against NHE1 or RNA purification, reverse transcription and qPCR with
primers against NHE1 and GAPDH, as described in the Methods section. NHE1 was inhibited by cariporide (10 μM) as indicated. a NHE1 mRNA
levels in HUVEC based on quantification of qPCR results relative to the untreated control and normalized to GAPDH levels. *** indicates p < 0.001,
ANOVA with Tukey’s multiple comparison post-test. Data are shown as means with SEM error bars of n = 5. b Representative western blot and
quantification (relative to Ctrl conditions), showing the protein expression levels of NHE1 in HUVEC after 24 h of TME or hypoxia exposure. GAPDH
is shown as loading control. Quantified data are shown as means with SEM error bars of n = 3–5. c Representative western blot and quantification
(relative to ctrl condition), showing the protein expression levels of NHE1 in HUVEC after 48 h of TME or hypoxia exposure. GAPDH is shown as
loading control. Quantified data are shown as means with SEM error bars of n = 3. d, e Effects of NHE1 siRNA knockdown and TME conditions were
evaluated using the Ea.hy926 cell line. Cells were treated with siRNA against NHE1 or scrambled control siRNA for 24 h prior to exposure to
TME conditions. d NHE1 mRNA levels in Ea.hy926 quantified as in (A). Data are shown as means with SEM error bars, and n = 5. e Western blot
analysis of NHE1 protein levels in Ea.hy926. p150 is shown as loading control. Representative of n = 3
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protein rpS6 [29, 33]. Western blotting showed that the
level of Thr389-phosphorylated, active p70S6K was dra-
matically decreased under TME conditions in HUVEC
(Fig. 5a). Hypoxia alone also reduced p70S6K phosphor-
ylation, although to a much lesser extent. Interestingly,
NHE1 inhibition by cariporide further reduced the
Fig. 3 TME conditions dramatically lower mRNA and protein levels of Akt1 in HUVEC and Ea.hy926 cells, associated with increased relative phosphorylation
of Akt. Cells were exposed to normoxic control (Ctrl), TME (1% O2, 1% FBS, 2.5 mM glucose, 7.5 mM lactate and pH 6.5) or hypoxic (Hyp; 1% O2) conditions
as indicated, for 24 h before lysis and RNA purification, reverse transcription and qPCR or western blotting, as indicated. a Relative mRNA levels of the three
Akt isoforms Akt1–3 in HUVEC (left panel) and Ea.hy926 (right panel) under Ctrl conditions. b Relative mRNA levels of Akt1–3 in HUVECs exposed to Ctrl,
TME or Hyp conditions. Data are shown as means with SEM error bars and n = 5. * and ** denotes p < 0.05 and p < 0.01, respectively, one-way
ANOVA with Tukey’s multiple comparison post-test. c Akt1 and p-Ser473Akt levels in HUVEC cells after 24 h of Ctrl, TME or Hyp conditions in
the absence or presence of 10 μM cariporide. Top: representative western blots (GAPDH is shown as loading control), middle: protein level of
total Akt1, bottom: p-Ser473Akt normalized to total Akt1. d As C, except for Ea.hy926 cells treated with NHE1 siRNA or scrambled control siRNA, and
exposed to Ctrl or TME conditions. p150 is shown as loading control. Data are shown as means with SEM error bars, relative to control, and n = 3
for Hyp conditions, n = 5 for all other conditions. *** denotes p < 0.001, two-way ANOVA with Bonferroni’s multiple comparison post-test. The
test revealed a significant difference in Akt1 protein levels between conditions (Ctrl, TME, Hyp), p < 0.01 for HUVEC and between conditions
(Ctrl, TME), p < 0.0001 for Ea.hy926 cells
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hypoxic level of Thr389-p70S6K. rpS6 is a target of
p70S6K, and accordingly, the Ser235/236-phosphoryl-
ation of rpS6 was substantially reduced in HUVEC
under TME conditions, whereas it was unaffected by
hypoxia alone (Fig. 5b). A similar trend was seen after
TME exposure in Ea.hy926 cells (Fig. 5c). rpS6 phos-
phorylation was unaffected by cariporide in both cell
lines (Fig. 5b, c). Whereas rpS6 phosphorylation by the
Akt - p70S6K pathway correlates with increased protein
translation, phosphorylation of the translation initiation
factor eIF2α at Ser51 by one of several eIF2α kinases re-
duces the rate of protein translation by stabilizing the
GDP bound state of eIF2α, rendering it inactive [40].
Notably, in HUVEC, the phosphorylation level of eIF2α
was increased by TME exposure, yet unaffected by hyp-
oxia alone, consistent with reduced protein translation
(Fig. 5d), and a similar pattern was seen in Ea.hy926 cells
(Fig. 5e). The phosphorylation state of eIF2α was in-
sensitive to cariporide in both cell types (Fig. 5d, e).
These results reveal a remarkable difference between
the impact of TME and of hypoxia alone on translation
in endothelial cells: several branches of the translational
machinery are negatively regulated by TME conditions,
yet unaffected by hypoxia alone.
TME, but not hypoxia, reduces proliferation and induces
apoptosis signaling in endothelial cells
We next asked whether the much more potent effects
of TME conditions compared to hypoxia alone would
translate into different effects of the two conditions on
endothelial cell proliferation and survival. We first
determined the effects of TME and hypoxia on prolifer-
ation signaling in HUVEC and Ea.hy926 cells, using p-
Ser807/811-retinoblastoma protein (p-pRb) as a marker
of the level of cell proliferation (Ser807/811 phosphor-
ylation of pRb allows G1 progression [41]). In HUVEC,
neither TME nor hypoxia markedly affected pRb phos-
phorylation after 24 h of exposure (Fig. 6a), but after
48 h, TME conditions had induced a ~ 50% decrease in
the p-pRb level, whereas there was no effect of hypoxia
(Fig. 6b). Ea.hy926 cells responded more rapidly to
TME conditions, with a decreased p-pRb level detect-
able after 24 h of TME exposure (Fig. 6c). There was
no effect of either cariporide (Fig. 6a, b) or NHE1
knockdown (Fig. 6c) on pRb phosphorylation.
To evaluate apoptotic cell death induction, we evalu-
ated the appearance of the 89 kDa cleavage product of
poly-ADP-ribose polymerase (PARP) [42]. HUVEC ex-
hibited a marked increase in PARP cleavage after 24 h
Fig. 4 Treatment of HUVECs with tumor conditioned medium increases Akt, but not NHE1, protein expression. a VEGF content in MCF-7 conditioned
medium (MCF-7 CM) based on quantification of ELISA results. MCF-7 cells were grown under TME conditions (1% O2, 1% FBS, 2.5 mM glucose, 7.5 mM
lactate and pH 6.5) for 24 h, and medium collected for ELISA. Data are presented as mean with SEM error bar (n = 4). ** indicates p < 0.01, one-sample
Student’s t-test against baseline. b, c HUVECs were exposed to standard TME conditions or to TME conditions with freshly prepared MCF-7 CM for 24 h
followed by lysis and western blotting. Representative western blots and quantification of total protein levels relative to that for cells grown under
standard TME conditions are shown for Akt1 (b) and NHE1 (c). GAPDH is shown as loading control. Data are presented as means ± SEM, with n = 4 per
condition. * indicates p < 0.05, two-tailed paired Student’s t-test
Pedersen et al. BMC Cancer  (2017) 17:542 Page 9 of 15
of TME conditions, whereas neither hypoxia alone nor
cariporide treatment affected PARP cleavage (Fig. 6d).
Taken together, these data indicate that TME ex-
posure, but neither hypoxia nor NHE1 inhibition,
reduces proliferation and induces apoptosis in endothe-
lial cells.
Discussion
In the great majority of cancers, neo-vascularization is
essential for continued tumor growth [1–3]. Hypoxia is
only one component of the TME, which is additionally
characterized by low levels of nutrients and glucose, ele-
vated lactate, and low pHe, and the presence of VEGF
Fig. 5 TME conditions regulate the phosphorylation levels of p70S6K, rpS6 and eIF2α. HUVECs or Ea.hy926 were exposed to normoxic control (Ctrl),
TME (1% O2, 1% FBS, 2.5 mM glucose, 7.5 mM lactate and pH 6.5) or hypoxic (Hyp; 1% O2) conditions as indicated, followed by lysis and
western blotting. NHE1 was inhibited by cariporide (10 μM) or knocked down by siRNA-treatment where indicated. a Representative western
blots of p-Thr389p70S6K and total p70S6K and quantification of p-p70S6K protein levels normalized to total p70S6K and relative to the untreated
control condition for 24 h for HUVEC. GAPDH is shown as a loading control. b, c Representative western blots of p-Ser235/236rpS6 and quantifications
of p-rpS6 protein levels relative to the untreated control condition for 24 h for HUVEC (b) and Ea.hy926 (c). GAPDH and p150 are shown as loading
controls. d, e Representative western blots of p-Ser51eIF2α and quantifications of p-eIF2α protein levels relative to the untreated control condition
for 24 h for HUVEC (d) and Ea.hy926 (e). p150 is shown as loading control. Data are presented as means with SEM error bars, with n = 5 except
Hyp without/with cariporide for which n = 3. *, ** and *** indicates p < 0.05, p < 0.01 and p < 0.001, respectively, as obtained by two-way
ANOVA with Bonferroni’s multiple comparison post-test. The two-way ANOVA test revealed a significant difference in p-p70S6K/p70S6K (p < 0.0001),
p-rpS6 (p < 0.0001 for HUVEC and p < 0.05 for Ea.hy926) and p-eIF2α (p < 0.05 for HUVEC and p < 0.01 for Ea.hy926) between conditions (Ctrl, TME,
Hyp). Also, p-p70S6K/p70S6K significantly changed with cariporide (p < 0.01)
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and numerous other cytokines and growth factors [8].
Although it is well established that these other TME
components can exert a profoundly different gene-
regulatory effect than hypoxia alone [9–12] very few
studies have directly compared the effects of hypoxia
versus a more complex TME on angiogenic signalling.
The Na+/H+ exchanger NHE1 plays a major role in can-
cer development [14, 15], is regulated by hypoxia [27,
43] and was recently proposed to play a role in HIF-1α-
induced angiogenesis [25], yet its roles in endothelial cell
signaling under hypoxia as compared to TME conditions
have not been studied. The aims of this work were,
therefore, to investigate the effects of a complex TME
versus hypoxia alone on two different endothelial cell
lines and to evaluate the possible roles of NHE1 in the
endothelial cell response to TME and hypoxia.
Fig. 6 TME conditions decrease proliferation and increase apoptosis signaling, while hypoxia alone has no effect. HUVECs or Ea.hy926 were exposed
to normoxic control (Ctrl), TME (1% O2, 1% FBS, 2.5 mM glucose, 7.5 mM lactate and pH 6.5) or hypoxic (Hyp; 1% O2) conditions as indicated, for 24 or
48 h followed by lysis and western blotting. NHE1 was inhibited by cariporide (10 μM) or knocked down by siRNA-treatment where indicated. GAPDH
is shown as loading control. a, b, c Representative western blots of p-Ser807/811-pRb and quantifications of the p-pRb protein levels relative to the
untreated control condition for 24/48 h for HUVEC (a, b) and 24 h for Ea.hy926 (c). Two-way ANOVA revealed a significant difference in p-pRb levels
between conditions (Ctrl, TME, Hyp) with p < 0.05 for HUVEC and p < 0.01 for Ea.hy926, respectively. d Representative western blots showing PARP
protein levels and quantification of cleaved PARP relative to the untreated control for 24 h in HUVEC. Data are presented as means with SEM error bars,
with n = 3–5
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HIF-1α and VEGF are induced more potently by TME than
by hypoxia alone
It is well established that HIF-1α activation is induced
in response to hypoxia in endothelial cells, and that
HIF-1α mediates increased expression of VEGF and
other angiogenic factors leading to endothelial cell acti-
vation [44]. We show here that TME had a much stron-
ger effect on HIF-1α and VEGF expression than
hypoxia alone, demonstrating that other components of
the TME potentiate this response. A very likely candi-
date is lactate, which was previously found to induce
HIF-1α protein expression and activity in HUVEC. The
mechanism involves lactate uptake via monocarboxylate
transporter 1 (MCT1) conversion to pyruvate, and in-
hibition of prolyl hydroxylase 2 (PHD2), preventing
HIF-1α degradation [45, 46]. A lactate-induced increase
in released VEGF from HUVEC was not detectable
[46]. In contrast, lactate elicited upregulation of
VEGFR2, which would potentiate signaling by VEGF
released by the cancer cells in a tumor [45, 46]. Inter-
estingly, VEGF mRNA levels in HUVEC were increased
after 48 h exposure to 10 mM lactate [47], consistent
with our finding after TME exposure. Collectively, this
suggests that mRNA levels of VEGF in HUVEC are
modestly increased by lactate as well as by TME, yet do
not elicit detectable VEGF release, in contrast to the ro-
bust VEGF release measured from TME-treated MCF-7
breast cancer cells.
Another possible effector is acidic pHe, which has been
shown to increase HIF-1α stability in several cell types, by
mechanisms proposed to involve repression of the PHD2/
von Hippel-Lindau (VHL) pathway [48] or a heat shock
protein 90 (HSP90)-dependent pathway [49]. In other cell
types no or only a slight enhancement of HIF-1α expres-
sion was reported [50]. Low pHe was also shown to in-
crease VEGF production in glioblastoma cells in a HIF-1α
–independent, ERK1/2/AP-1-dependent manner [51].
NHE1 inhibition or knockdown had marginal or no
effect on the other studied signaling events elicited by
TME or hypoxia (discussed in the following sections).
This was initially unexpected as a 0.2–0.3 pH unit de-
crease in HUVEC pHi after NHE1 knockdown was pre-
viously reported [25]. However, these measurements
were carried out in PBS solution, preventing pHi regu-
lation by the Na+, HCO3
−-cotransporters which are
known to play a major role in this process in most
endothelial cells [14], and hence are unlikely to reflect
the physiological situation.
Thus, we conclude that TME robustly upregulates
HIF-1α and VEGF expression in endothelial cells in a
manner that may involve effects of lactate and/or
acidic pHe in addition to hypoxia. Further, we con-
clude that in the cell types studied here, this upregu-
lation does not involve NHE1.
NHE1 is downregulated by TME and hypoxia, and its
knockdown reduces endothelial cell migration but has no
effect on other TME-induced signaling events
In contrast to the increase in HIF-1α and VEGF, the
mRNA level of NHE1 was strongly reduced by both
TME and hypoxia conditions. The NHE1 protein level
also decreased in Ea.hy296 cells after 24 h of TME, but
not in HUVEC over 48 h. This may be related to slower
protein degradation (basal or TME induced) in HUVEC,
the reported half-time for NHE1 in the membrane under
normal conditions being about 24 h as measured in
fibroblasts and epithelial cells [52]. The reduction of
NHE1 protein expression by hypoxia is consistent with
recent work in which 48 h of 2% hypoxia or exposure to
the HIF-1α stabilizer Dimethyloxaloylglycine (DMOG) re-
duced NHE1 protein levels in some cancer cell lines [27].
In contrast, NHE1 was upregulated in cerebral micro-
vascular endothelial cells (CMEC) exposed for 1–5 h to
hypoxia [24] and in pulmonary arterial myocytes after
3 weeks at 10% O2 [26], suggesting dose- and cell-type-
dependent differences in the effects of hypoxia on NHE1
expression. Interestingly, in CMEC, upregulation of NHE1
by hypoxia was greater at 7% than at 2% oxygen [24], hint-
ing that the cell type differences may involve a balance be-
tween hypoxia-induced signals favoring NHE1 up- and
downregulation. Importantly, it is clear that the more
physiologically relevant TME and hypoxia conditions used
here do not recapitulate the reported upregulation of
NHE1 in HUVEC after lentiviral HIF-1α overexpression
[25].
Importantly, consistent with the known role of NHE1
in the motility of a wide range of cell types [39], knock-
down of NHE1 in Ea.hy926 cells – i.e. resembling the
effect of TME on these cells – reduced their motility in
a scratch wound assay by 50%. The observed reduction
in the NHE1 level under TME conditions is therefore
likely to result in reduced endothelial cell motility under
these conditions.
Akt and its downstream effectors are regulated by TME
but not by hypoxia
Consistent with earlier reports on Akt isoform expres-
sion in endothelial cells, [32] HUVECs expressed Akt1,
−2, and −3, yet Akt1 was by far the most abundant [32].
The decrease in Akt expression under TME conditions
was seen both at the mRNA and protein levels, whereas
hypoxia alone modestly decreased the Akt1 mRNA level,
but had no effect on the protein level. This suggests that
Akt protein stability may be decreased by factors in the
TME. The mechanisms, although not further studied
here, could include the low serum content of TME
medium, as it has been shown that serum deprivation
downregulated Akt in HUVEC [53]. Supporting our
finding that the VEGF-enriched, cancer cell conditioned
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medium rescued Akt1 expression, the same study
showed that culturing cells with VEGF prevented down-
regulation of Akt in response to serum deprivation [53].
Also in congruence with our findings, tumor condi-
tioned medium was shown to increase Akt activity in
microvascular endothelial cells in a VEGFR2 dependent
manner [54].
Akt positively regulates cell growth and protein syn-
thesis through activation of mTORC1 and downstream
activation of the p70S6 kinase and regulation of down-
stream substrates rpS6 and eIF4B [29, 33, 40]. TME elic-
ited reduced phosphorylation of both p70S6K and rpS6,
which is in accordance with the reduced total Akt level,
but surprising given that the total Akt phosphorylation
was not reduced by TME. The underlying mechanisms
are not clear, but an isoform shift in Akt activity is pos-
sible, since the different Akt isoforms have different
downstream effects [30–32]. Furthermore, as lack of nu-
trients and energy (low levels of growth factors, glucose,
amino acids and oxygen) results in inhibition of mTORC
via complex signaling events not only downstream of
Akt [33], this could in principle contribute to the ob-
served effects of TME on p70S6K and consequently
rpS6. Although the precise mechanisms mediating the
phosphorylation of eIF2α under TME conditions remain
to be determined, eIF2α phosphorylation is induced by
several different kinases under stress conditions, includ-
ing endoplasmic reticulum (ER) stress [40]. Notably,
mechanisms have evolved for specific transcripts to
evade general inhibition of protein synthesis as under
TME conditions. These mechanisms are often exploited
to induce translation of adaptive proteins under condi-
tions of cellular stress. An example is the presence of in-
ternal ribosome entry sites (IRESs), which are present in
~10% of all mRNAs and allow translation when regular
cap-dependent translation is inhibited. VEGF contains
two IRESs [55, 56] and the presence of these could me-
diate expression of VEGF under TME conditions even
though global translation was inhibited.
Implications for endothelial cell function in the tumor
microenvironment in vivo
TME treatment reduced proliferation signaling and in-
duced PARP cleavage in the endothelial cells, a finding
supported by earlier reports that HUVEC undergo
caspase-dependent death upon deprivation of serum/
nutrients [28, 53], and by a recent report showing that
HUVEC proliferation is reduced by acidic pHe [57].
The results also fit well with the downregulation of
Akt, which normally favors cell proliferation and
counteracts cell death via phosphorylation-mediated
regulation of e.g. GSK3 and BAD [33]. It is surprising
that NHE1 knockdown does not further exacerbate
these effects, given the known roles of this transporter
in growth and survival under stress conditions [58],
however, it may simply be that knockdown has no fur-
ther effect on proliferation and death because of the
already decreased NHE1 levels under TME conditions.
It is possible that similar to Akt (but not NHE1) ex-
pression, the effects of TME on proliferation and sur-
vival are at least partially compensated in vivo, e.g. by
VEGF and survival factors released from the cancer
cells and other stromal cells [8]. Given their markedly
different genetic profiles [59, 60], it also seems likely
that TME elicits different signaling events in tumor
endothelial cells than in normal endothelial cells, and
this should be assessed in future studies. It is known,
for instance, that endothelial cells at the forefronts of
sprouts are capable of adapting to severe hypoxia,
since most of their energy is obtained through anaer-
obic glycolysis [61, 62]. In addition, microvascular
(but not macrovascular) endothelial cells express
vacuolar-type H+-ATPases at the membrane [63], and
could thus be able to maintain a relatively normal pHi
during periods of increased glycolysis, as in the hyp-
oxic microenvironment of tumors.
Conclusions
In conclusion, we show here that TME conditions up-
regulate HIF-1α and VEGF, and downregulate NHE1
and Akt, in endothelial cells, much more potently than
does hypoxia alone. The downregulation of Akt can
partially be compensated by cancer cell conditioned
medium. Likely downstream from the decrease in Akt
expression, TME exposure elicits reduced p70S6K and
rpS6 phosphorylation and increases eIF2α phosphory-
lation, consistent with reduced protein translation. Fi-
nally, TME elicits reduced proliferation and increased
apoptosis signaling. These effects are independent of
NHE1, yet knockdown of NHE1 to levels similar to
those induced by TME strongly reduces endothelial cell
migration.
Additional file
Additional file 1: Figure S1. TME downregulates Akt1 and −2, but not
−3 mRNA levels in Ea.hy926 cells. Cells were exposed to the normoxic
control (Ctrl), or TME (1% O2, 1% FBS, 2.5 mM glucose, 7.5 mM lactate
and pH 6.5) conditions for 24 h before lysis and RNA purification, reverse
transcription and qPCR. The graphs show the relative mRNA expression
levels of the three Akt isoforms Akt1–3 in Ea.hy926 exposed to Ctrl, or
TME conditions and treated with siRNA targeting NHE1 as indicated.
Results were based on quantification of qPCR results obtained using specific
primers against Akt1, −2 or −3 and normalized to GAPDH. Data are shown
as means with SEM error bars and n = 5. ** and *** denotes p < 0.01 and
p < 0.001, respectively, acquired using two-way ANOVA with Bonferroni’s
multiple comparison post-test. (TIFF 1715 kb)
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